Acumen Pharmaceuticals (ABOS) Total Non-Current Liabilities (2023 - 2025)

Acumen Pharmaceuticals has disclosed Total Non-Current Liabilities across 3 years of filings, most recently posting $52.4 million for Q4 2025.

• In Q4 2025, Total Non-Current Liabilities fell 8.11% year-over-year to $52.4 million; the TTM figure through Dec 2025 stood at $52.4 million (down 8.11% YoY), while the FY2025 annual figure was $52.4 million, down 8.11% from the prior year.
• Total Non-Current Liabilities came in at $52.4 million for Q4 2025 at Acumen Pharmaceuticals, up from $49.0 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $57.0 million in Q4 2024 to a low of $42.9 million in Q4 2023.
• Average Total Non-Current Liabilities over 3 years is $50.8 million, with a median of $50.7 million recorded in 2025.
• Year-over-year, Total Non-Current Liabilities jumped 33.03% in 2024 and dropped 8.11% in 2025.
• Over 3 years, Total Non-Current Liabilities stood at $42.9 million in 2023, then surged by 33.03% to $57.0 million in 2024, then declined by 8.11% to $52.4 million in 2025.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $52.4 million in Q4 2025, $49.0 million in Q3 2025, and $54.7 million in Q2 2025.